Payment overview · 2025
General Payments
$65.34
3 reported records · 3 companies
Healthcare provider profile · identity verified
Christopher Foret, MD.
Allopathic & Osteopathic Physicians|Family Medicine · FOLSOM, LA · NPI 1245251602
Verified facts
What the public records show
CMS Open Payments records show Christopher Foret, MD. received $65.34 in general payments during 2025 across 3 reported records.
Medtronic, Inc. accounted for 49.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$32.16 | 49.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.38 | 26.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.80 | 24.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $65.34 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $32.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 96 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 828 | 252 |
| Amlodipine Besylate | Amlodipine Besylate | 714 | 220 |
| Levothyroxine Sodium | Levothyroxine Sodium | 550 | 143 |
| Pantoprazole Sodium | Pantoprazole Sodium | 395 | 120 |
| Ezetimibe | Ezetimibe | 387 | 116 |
| Losartan Potassium | Losartan Potassium | 343 | 102 |
| Metformin Hcl | Metformin Hcl | 284 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 60 |
| Lisinopril | Lisinopril | 188 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 46 |
| Gabapentin | Gabapentin | 160 | 51 |
| Metformin Hcl Er | Metformin Hcl | 159 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 44 |
| Montelukast Sodium | Montelukast Sodium | 132 | 32 |
| Furosemide | Furosemide | 129 | 39 |
| Celecoxib | Celecoxib | 128 | 42 |
| Trulicity | Dulaglutide | 119 | 23 |
| Potassium Chloride | Potassium Chloride | 118 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 38 |
| Allopurinol | Allopurinol | 117 | 40 |
| Famotidine | Famotidine | 116 | 44 |
| Alendronate Sodium | Alendronate Sodium | 115 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 37 |
| Clonazepam | Clonazepam | 111 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 31 |
| Jardiance | Empagliflozin | 107 | 21 |
| Irbesartan | Irbesartan | 105 | 37 |
| Omeprazole | Omeprazole | 104 | 31 |
| Lorazepam | Lorazepam | 100 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 33 |
| Ramipril | Ramipril | 99 | 29 |
| Eliquis | Apixaban | 96 | 24 |
| Ozempic | Semaglutide | 94 | 19 |
| Valsartan | Valsartan | 88 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 23 |
| Synthroid | Levothyroxine Sodium | 77 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 21 |
| Trazodone Hcl | Trazodone Hcl | 70 | 20 |
| Alprazolam | Alprazolam | 68 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 16 |
| Finasteride | Finasteride | 66 | 18 |
| Sertraline Hcl | Sertraline Hcl | 65 | 20 |
| Atenolol | Atenolol | 64 | 18 |
| Carvedilol | Carvedilol | 62 | 18 |
| Mirtazapine | Mirtazapine | 60 | 18 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 15 |
| Clonidine Hcl | Clonidine Hcl | 54 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 12 |
| Benazepril Hcl | Benazepril Hcl | 41 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 15 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Fenofibrate | Fenofibrate | 38 | 13 |
| Glipizide Er | Glipizide | 38 | 12 |
| Spironolactone | Spironolactone | 38 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 34 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 31 |
| Lubiprostone | Lubiprostone | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Prednisone | Prednisone | 21 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 17 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $65.34 · 3 records | Medtronic, Inc. | ELIQUIS, FARXIGA, NURTEC ODT, PROTEGE RX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error